[1] Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology, 2012,142: 1431-1443.
[2] Blaya D, Coll M, Rodrigo-Torres D, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut, 2016, 65: 1535-1545.
[3] Yang Y,Zhang J,Xia T,et al.MicroRNA-210 promotes cancer angiogenesis by targeting fibroblast growth factor receptor-like 1 in hepatocellular carcinoma. Oncol Rep,2016,36: 2553-2562.
[4] Li M, He Y, Zhou Z, et al. MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils. Gut, 2017,66: 705-715.
[5] Macchi F, Comments on assessment of drug-induced liver injury in clinical practice by Lucena MI et al. Fundamental & amp; Clinical Pharmacology 2008; 22: 141-158. Fundam Clin Pharmacol,2008,22: 613.
[6] Vickers KC, Landstreet SR, Levin MG, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A, 2014,111: 14518-14523.
[7] Yang F, Lou G, Zhou X, et al. MicroRNA-223 acts as an important regulator to Kupffer cells activation at the early stage of Con A-induced acute liver failure via AIM2 signaling pathway. Cell Physiol Biochem, 2014, 34: 2137-2152.
[8] Qadir XV, Chen W, Han C, et al. miR-223 Deficiency Protects against Fas-Induced Hepatocyte Apoptosis and Liver Injury through Targeting Insulin-Like Growth Factor 1 Receptor. Am J Pathol, 2015,185: 3141-3151.
[9] Xu J, Wu C, Che X,et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 2011,50: 136-142. |
